← All agents | ← Research tracker
Maraviroc
PubChem entry
Evidence Summary
Evidence Level: Preliminary
Mechanism: Enrollment: Estimated, Sponsor Type: Industry, Unknown / General
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
CCR5 antagonist studied for persistent immune activation (often + statin). 300mg BID; LFT monitoring. Very early/experimental for these conditions.
Related Conditions
Long COVID (no page yet)
Clinical Trials
1 trial(s) registered
NCT06974084: A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the PHASE2 NOT_YET_RECRUITING
Key Studies / References